Answers are grounded in this paper and cite their sources.
OBJECTIVES: This study explores the expression of intracytoplasmic TLRs across diverse B cell subtypes in lupus, their association with renal activity, and their prognostic value. METHODS: We compared TLR7, TLR9, and MyD88 expression across peripheral B cell subtypes by flow cytometry, along with 29 cytokines serum levels from 28 LN patients and 26 lupus patients with extrarenal activity (NLN). After induction therapy, TLRs/MyD88 expression was reanalysed according to treatment response in LN. RESULTS: LN patients were characterised by higher frequency of MyD88+ B cells (86.5% vs 52.65%, p 0.04), predominantly in transitional cells (97.7% vs 58.7%, p 0.03). Treatment-adjusted analysis revealed the association of TLR7⁺ naïve B cells (OR 1.02, p 0.01) and TLR9 mean fluorescence intensity (MFI) in transitional B cells (OR 1.008, p 0.004) with LN. The latter, together with eotaxin (OR 1.01, p 0.01), constitute the proposed LN association model (OR 1.006 and 1.01 p 0.01, respectively). At 6-month follow-up, the responder group showed persistently elevated expression of TLR7 and TLR9 in naïve and atypical B-cell subsets, including double-negative (DN) and age-associated B cells (ABCs). The association model for renal response included TLR7 MFI in naïve B cells (OR 1 p 0.05) and TLR9 MFI in ABCs (OR 1.001 p 0.03). CONCLUSION: In LN, increased MyD88 and TLR7/TLR9 expression in early B-cell stages may promote autoreactive cell survival and differentiation into autoantibody-secreting cells, contributing to immune complex deposition and eotaxin-sustained renal inflammation. In contrast, higher TLR9 in TLR7-dependent subsets may exert a regulatory effect that, alongside induction therapy, favours nephritis resolution.
No takes yet. Share an insight, caveat, or question.
Balderas-Miranda et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: